• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - weight loss
Tag:

weight loss

Health

6 Surprising Habits That Are Ruining Your Gut Health

by Chief Editor June 17, 2026
written by Chief Editor

Modern gut health trends are shifting away from quick-fix supplements toward sustainable, long-term dietary habits. Medical professionals warn that reliance on probiotics and off-label weight loss medications like GLP-1 agonists often overlooks the necessity of a diverse, naturally nurtured microbiome. True digestive health requires time and consistency rather than pharmaceutical shortcuts or additive-heavy health products.

Why are probiotics often ineffective?

Probiotics—supplements containing live bacteria—are frequently over-prescribed or misused, according to clinical observations. While these supplements have a legitimate medical role, they are not a universal solution for digestive issues. Many commercial probiotic yogurts and drinks contain high levels of added sugars and artificial additives, which can counteract potential benefits.

According to gastroenterology experts, the human gut microbiome is highly individualized. A strain that provides benefit to one person may fail to colonize in another. Over-consumption of these products can lead to bloating, cramps, and altered bowel habits, such as constipation or diarrhea. In some instances, patients report non-specific symptoms like brain fog or persistent drowsiness after starting a new probiotic regimen.

Did you know? Probiotics rarely cause long-term harm or infections, but they are often unnecessary for healthy individuals who already consume a balanced, fiber-rich diet.

Are GLP-1 agonists changing gut health?

The rise of GLP-1 receptor agonists, such as Ozempic and Wegovy, has introduced new risks for patients seeking weight loss solutions. While these medications are clinically validated for treating type 2 diabetes and obesity, their use as a “lifestyle choice” has sparked concern among medical practitioners. Because some pharmacies now offer these drugs without a formal GP consultation, users may bypass critical monitoring for significant side effects.

Are You Ruining Your Gut? 3 Surprising Habits to Stop Today!

The shift toward using powerful metabolic medications for non-clinical weight management represents a departure from traditional gut health protocols. Unlike lifestyle-based gut nurturing, which focuses on ecosystem diversity, these drugs alter hormonal signaling. Patients considering these medications should consult with a healthcare provider to understand the potential systemic consequences on their digestive function.

How can you support a healthy microbiome?

Building a healthy gut is a slow process that mirrors planting a tree; it requires patience and consistent, sustainable behaviors. Experts emphasize that there is no “hack” to bypass the need for a diverse diet. A stable microbiome is built through long-term habits, such as increasing fiber intake and reducing reliance on processed foods, rather than looking for a single supplement or pharmaceutical intervention.

Pro Tip: Before starting any supplement, track your symptoms for two weeks. If your bowel habits or energy levels do not improve, consult a professional rather than switching to a more expensive brand.

Frequently Asked Questions

  • Should I stop taking probiotics if I feel fine? If you are not experiencing specific symptoms and your diet is balanced, many experts suggest you may not need them at all.
  • Are all probiotics bad for you? No, but many mass-market versions contain high levels of sugar and additives. Always check labels for unnecessary ingredients.
  • Can I use GLP-1 drugs without a doctor’s supervision? Medical experts strongly advise against this. These are potent medications that require professional monitoring to manage potential side effects.
  • How long does it take to improve gut health? Improving the microbiome is a long-term process. It takes time for the gut ecosystem to adapt to new, healthy, sustainable behaviors.

Have you struggled to find a gut health routine that works? Share your experiences in the comments below or subscribe to our newsletter for more evidence-based health insights.

June 17, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

What Happens to Your Body During a 36-Hour Fast: A Simulation

by Chief Editor June 12, 2026
written by Chief Editor

Intermittent fasting, a dietary pattern involving scheduled cycles of eating and abstinence, triggers significant metabolic shifts but carries notable health risks, according to clinical reports. While some simulation models suggest the body begins burning fat within hours, health organizations warn of side effects including fatigue, nutrient deficiencies, and the potential exacerbation of disordered eating patterns.

How does 36-hour fasting affect the body?

Extended fasting, such as a 36-hour window, forces the body to transition from glucose metabolism to fat oxidation. According to educational content from the YouTube channel Wellness Wise, the body initiates these changes within the first few hours of abstinence. However, medical professionals caution that these physiological shifts are not inherently beneficial for every individual. The Emily Program, a specialized eating disorder treatment service, notes that while weight loss may occur, the body often experiences stress responses, including increased hunger pangs and fluctuating energy levels, as it attempts to maintain homeostasis without a consistent caloric intake.

Did you know?
The metabolic shift toward fat burning is often cited as a primary benefit of fasting, yet experts like James Betts, a professor of metabolic physiology at the University of Bath, argue that human-scale evidence for dramatic, long-term health benefits remains sparse.

What are the common side effects of restrictive dieting?

Restrictive eating protocols often lead to predictable physical and psychological consequences. The Emily Program identifies several common side effects associated with intermittent fasting, including:

What are the common side effects of restrictive dieting?
  • Physical: Dizziness, headaches, digestive issues such as bloating or constipation, and dehydration.
  • Metabolic: Polyuria (excessive urination) and potential nutrient deficiencies.
  • Psychological: Increased irritability, sleep disturbances, and fatigue.

These symptoms vary in severity depending on the individual’s history and current health status. Unlike standard caloric restriction, intermittent fasting specifically asks individuals to ignore internal hunger cues, which clinicians warn can disrupt a person’s natural relationship with food.

Why is the long-term sustainability of fasting questioned?

Research into intermittent fasting remains limited in both size and duration, making it difficult to establish long-term efficacy. The Emily Program reports high drop-out rates in clinical trials, suggesting that the regimen is difficult for many participants to maintain. Professor James Betts told The Guardian that while the concept of “running on fats” sounds appealing, the dramatic health benefits often touted in wellness circles have not been consistently borne out in human studies. The lack of robust, long-term data stands in contrast to the rapid growth of fasting as a social media health trend.

Pro Tip:
Before attempting any major dietary change, consult with a registered dietitian or physician to assess whether the protocol aligns with your specific health needs and history.

Frequently Asked Questions

Is intermittent fasting considered an eating disorder?

No, intermittent fasting is a dietary pattern, not a clinical eating disorder. However, The Emily Program warns that ignoring hunger cues can foster disordered eating habits in susceptible individuals.

I Fasted for a Week & This Happened! #fasting #wisewellnesswisdom #weightlossstrategies

Does fasting guarantee weight loss?

While fasting can lead to weight loss through caloric restriction, it is not a universally sustainable method. Many studies show high attrition rates, meaning participants struggle to stick with the diet over time.

What should I do if I feel dizzy while fasting?

Dizziness is a common side effect of fasting. If you experience this, health experts recommend breaking the fast immediately and consulting a medical professional to ensure your blood sugar or hydration levels are not at risk.


Have you experimented with different dietary patterns? Share your experiences in the comments below or subscribe to our newsletter for the latest evidence-based health updates.

June 12, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Could Ozempic Be a Secret Weapon for ADHD?

by Chief Editor June 11, 2026
written by Chief Editor

Patients taking GLP-1 receptor agonists, such as Ozempic and Wegovy, are reporting unexpected improvements in ADHD symptoms, including increased focus, reduced procrastination, and better impulse control. While no clinical trials currently substantiate these claims, Dr. Lenard Adler, director of the Adult ADHD Program at NYU Langone Health, confirms he has observed these anecdotal reports among his own patients, though he notes that weight loss or lifestyle changes may also contribute to these perceived benefits.

Why are GLP-1 users reporting ADHD symptom relief?

The primary theory behind the link involves the brain’s reward centers. According to Dr. Lenard Adler, preclinical research indicates that GLP-1 medications interact with areas of the brain responsible for motivation and impulse control. For individuals with ADHD, whose dopamine pathways often struggle to regulate motivation, these drugs may potentially stabilize the neurological “noise” that makes starting tasks difficult. Users on platforms like Reddit have described the effect as a “lifting of brain fog,” reporting a newfound ability to initiate and complete daily responsibilities.

Did you know?
GLP-1 receptor agonists like semaglutide and tirzepatide were originally developed to manage Type 2 diabetes. Their expansion into weight management and potentially neurodegenerative health marks a significant shift in how these medications are categorized in clinical practice.

Could weight loss be the actual cause?

Medical experts warn that the perceived ADHD benefits might be indirect rather than a direct result of the medication’s chemical mechanism. Dr. Adler suggests that the 15% to 25% weight loss typically seen in patients over a year could significantly influence mental clarity. Improved physical health, increased activity levels, and reduced systemic inflammation can all lead to better coping mechanisms for ADHD symptoms. Without controlled clinical trials, it remains difficult to isolate whether the drug is treating the ADHD directly or if the patient is simply functioning better due to improved physical wellness.

Adult ADHD with Lenard Adler, MD

What are the risks of using off-label treatments?

There are currently no active clinical trials listed on ClinicalTrials.gov investigating GLP-1s specifically as an ADHD treatment. Dr. Adler emphasizes that patients should never attempt to replace their traditional ADHD medications with GLP-1s without medical supervision. Combining stimulants or non-stimulants with GLP-1s requires careful coordination between a patient’s primary care physician and their psychiatrist to avoid adverse interactions or the mismanagement of existing conditions.

What are the risks of using off-label treatments?
Pro Tip:
If you are currently managing ADHD and considering a GLP-1, keep a daily symptom log for at least one month. Sharing this data with your prescribing physician provides them with concrete evidence to help evaluate how the medication is affecting your cognitive function compared to your baseline.

Frequently Asked Questions

  • Are GLP-1s approved to treat ADHD? No. Currently, they are FDA-approved for Type 2 diabetes and chronic weight management.
  • Should I stop my Adderall if I start Ozempic? Never stop prescribed ADHD medication without consulting your doctor, as it can lead to significant withdrawal or a return of severe symptoms.
  • Why do some people feel more focused on these drugs? The theory is that GLP-1s modulate the brain’s reward and dopamine pathways, which are often dysregulated in individuals with ADHD.

Are you currently taking a GLP-1 and noticed a change in your focus or productivity? Share your experiences in the comments below or subscribe to our health newsletter for the latest updates on emerging medication research.

June 11, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

First Clinical Guidelines for CKM Syndrome Released

by Chief Editor June 9, 2026
written by Chief Editor

The American Heart Association and the American College of Cardiology have introduced the first clinical practice guideline for cardiovascular-kidney-metabolic (CKM) syndrome, a framework designed to identify and manage the interconnected risks of heart, kidney, and metabolic diseases. Nearly 90% of U.S. adults possess at least one risk factor for the condition, such as obesity, high blood pressure, or abnormal blood sugar, according to the June 2026 guidelines published in the journals Circulation and JACC.

How is CKM Syndrome Staged?

Clinicians use a four-stage system to assess patient risk and determine appropriate medical interventions. According to the guidelines, this staging helps doctors move from prevention to treatment as disease progresses:

View this post on Instagram about Johns Hopkins School of Medicine
From Instagram — related to Johns Hopkins School of Medicine
  • Stage 1: Patients with excess weight or prediabetes, but no other metabolic or cardiovascular complications.
  • Stage 2: Individuals with metabolic risk factors like high blood pressure, abnormal lipids, or chronic kidney disease, but without diagnosed cardiovascular disease.
  • Stage 3: Patients with subclinical cardiovascular disease or high-risk chronic kidney disease, often identified through the PREVENT-CVD risk equations.
  • Stage 4: Individuals with established cardiovascular disease, such as heart failure, coronary heart disease, or stroke, alongside metabolic or kidney risk factors.

Why Do Heart, Kidney, and Metabolic Health Overlap?

Medical consensus increasingly views these systems as a single, integrated network rather than separate organ functions. Dr. Chiadi E. Ndumele, chair of the guideline committee at Johns Hopkins School of Medicine, notes that these conditions do not occur in isolation. By treating the body as an interconnected system, clinicians can address the root causes of disease before a major cardiac event occurs.

Why Do Heart, Kidney, and Metabolic Health Overlap?

This shift contrasts with older medical models that often treated hypertension, diabetes, and kidney dysfunction in silos. The new guidelines prioritize a holistic approach, recommending that doctors screen for social determinants of health—such as food insecurity or housing instability—which significantly impact a patient’s ability to maintain metabolic health.

Did you know?
Roughly 40% of U.S. adults and 21% of children and adolescents live with obesity, which acts as a primary driver for the development of CKM syndrome, according to data from the American Heart Association and the American College of Cardiology.

What Are the Latest Treatment Strategies?

The guideline emphasizes a combination of lifestyle modifications and targeted pharmacological therapy. For the first time, GLP-1-based medications are recommended for specific patients with obesity or Type 2 diabetes to reduce the risk of cardiovascular events.

What is CKM? New heart syndrome linked to obesity, diabetes & kidney disease

According to Dr. Fátima Rodriguez of Stanford Medicine, the "Life’s Essential 8" framework remains the gold standard for prevention. This includes:

  • Prioritizing regular physical activity.
  • Maintaining a heart-healthy diet.
  • Managing blood pressure, blood sugar, and cholesterol levels.
  • Ensuring quality sleep and avoiding tobacco use.

In cases where lifestyle changes and medication are insufficient, the guidelines state that metabolic and bariatric surgery may be considered as a therapeutic option to manage CKM syndrome progression.

Frequently Asked Questions

What is the primary goal of the new CKM syndrome guidelines?
The goal is to identify cardiovascular, kidney, and metabolic risks earlier through a unified staging system, allowing for proactive, coordinated care to prevent severe organ damage.

Frequently Asked Questions

How does the new PREVENT-CVD equation differ from older tools?
The PREVENT equations offer a more precise estimation of 10- and 30-year cardiovascular risk by explicitly incorporating kidney and metabolic health markers.

Are GLP-1 medications recommended for everyone with CKM syndrome?
No. These medications are recommended for select individuals who meet specific criteria regarding obesity, Type 2 diabetes, and cardiovascular risk factors.

How can I reduce my risk of developing CKM syndrome?
Adopting the American Heart Association’s "Life’s Essential 8" is the primary recommendation. This includes managing weight, blood pressure, and nutrition to protect heart, kidney, and metabolic function simultaneously.


Are you managing your cardiovascular health? Talk to your primary care physician about the new CKM staging guidelines and how your metabolic and kidney health might influence your long-term heart risk. Subscribe to our newsletter for more updates on the latest medical breakthroughs.

June 9, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Can 15,000 Steps a Day Help You Lose Weight? Expert Insights

by Chief Editor June 8, 2026
written by Chief Editor

Walking 15,000 steps daily can support weight loss and improve metabolism, particularly for those transitioning from a sedentary lifestyle, according to Dr. Sarang Deshpande, a consultant in orthopaedics and joint replacement at KIMS Hospitals, Thane. While effective, experts emphasize that consistency, diet, and strength training are essential components of long-term fitness, as relying solely on step counts may not yield optimal results.

Can 15,000 steps really help you lose weight?

Walking is a low-impact exercise that helps burn calories and improves overall fitness, but it is not a standalone solution for weight loss. Dr. Deshpande notes that factors such as diet, sleep, stress, hormonal health, and age play critical roles. Someone who hits 15,000 steps daily but maintains a caloric surplus may struggle to lose weight. For most people, walking is easier to sustain over the long term compared to high-intensity workouts that are often abandoned.

Pro Tip: Don’t obsess over the 15,000-step mark. Dr. Deshpande suggests that 7,000 to 10,000 steps daily can provide significant health benefits if you maintain consistency.

Is 15,000 steps too much for the average person?

Jumping from a sedentary lifestyle to 15,000 steps a day can increase the risk of knee pain, ankle strain, heel pain, or lower back discomfort. Dr. Deshpande warns that the body requires time to adjust, especially for individuals who are overweight, have weak muscles, or suffer from early arthritis. A gradual increase in daily activity is safer than aggressively chasing numbers on a fitness tracker.

Is 15,000 steps too much for the average person?

Why strength training is the missing link

While walking is safer for the joints than high-impact activities like running or HIIT workouts, it is often insufficient for comprehensive fitness. According to Dr. Deshpande, strength training and flexibility exercises are vital because they build muscles that provide better joint support, thereby lowering the risk of future injury. Regular walking does help improve balance and maintain mobility, but it should be viewed as one part of a broader fitness routine.

Did you know? Walking is often recommended by orthopedists for middle-aged adults, seniors, or those with extra body weight because it exerts significantly less stress on the joints than high-impact training.

How to walk safely for better health

To maximize benefits while minimizing injury risk, prioritize proper gear and listen to your body. Dr. Deshpande advises wearing supportive footwear and staying hydrated, especially during warmer weather. If you experience persistent knee pain, swelling, or unusual breathlessness, stop pushing through the discomfort. Slow your pace and consult a medical professional to ensure your routine is appropriate for your specific health needs.

DRIFTx – Interview with Sarang Deshpande

Frequently Asked Questions

Is walking better than running for weight loss?

For many people, yes. Dr. Deshpande explains that walking puts less stress on the joints, making it a safer, more sustainable option for seniors, middle-aged adults, or those with excess weight.

What should I do if I feel pain while walking?

If you experience swelling, knee pain, or breathlessness, you should slow down immediately. It is important to seek medical advice rather than trying to push through the pain.

Do I have to hit 15,000 steps to see results?

No. Dr. Deshpande highlights that 7,000 to 10,000 steps daily can offer major health benefits, provided you are consistent with your activity levels.


Disclaimer: This article is based on information from the public domain and expert insights. Always consult your health practitioner before starting any new exercise routine.

Are you currently tracking your daily steps? Let us know your goals and progress in the comments section below, or subscribe to our newsletter for more expert fitness advice.

June 8, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Weight Loss Drugs May Prevent Obesity-Related Cancers

by Chief Editor June 8, 2026
written by Chief Editor

Research published in the journal Annals of Oncology indicates that GLP-1 receptor agonists (GLP-1 RAs) are associated with a 41% reduction in overall cancer risk among obese, non-diabetic adults. This study of more than 229,000 patients suggests these medications may offer significant benefits for cancer prevention beyond simple weight management.

Which cancers are linked to obesity?

Obesity is a known risk factor for a wide range of malignancies. According to the study, there are 13 specific “obesity-associated cancers.” These include:

  • Endometrial and ovarian cancers
  • Breast and bowel cancers
  • Kidney and pancreatic cancers
  • Thyroid, esophageal, and gastric cancers
  • Liver and gallbladder cancers
  • Multiple myeloma and meningioma

These specific types of cancer account for roughly 40% of all cancer diagnoses in high-income countries. Because the incidence of these cancers is rising rapidly among younger adults, researchers are looking closely at how weight management tools might intercept this trend.

Did you know?

Obesity-related cancers are becoming increasingly common in adults in their 40s and 50s, a demographic that often does not have diabetes but is increasingly using GLP-1 medications for weight control.

How much does cancer risk drop with GLP-1 RAs?

The study analyzed records from 229,467 obese, non-diabetic patients using the TriNetX nationwide database. After matching patients to ensure a fair comparison against those using diet and exercise alone, the results showed a significant downward trend in cancer incidence for those using GLP-1 RAs like semaglutide and tirzepatide.

View this post on Instagram about Related Cancers, Houston Methodist Hospital
From Instagram — related to Related Cancers, Houston Methodist Hospital

Dr. Aparna Kamat, director of the Division of Gynecologic Oncology at Houston Methodist Hospital, noted that the overall cancer risk reduction was 41%. However, the impact was even more pronounced in specific groups:

  • Men: Experienced a risk reduction of nearly 70%.
  • Endometrial Cancer: Incidence dropped by 58%. This is particularly notable as endometrial cancer is one of the malignancies most closely linked to excess body weight.

While all studied GLP-1 RA formulations reduced the incidence of obesity-related cancers, the researchers found that tirzepatide users saw the greatest reduction.

Do these benefits apply to everyone?

The research highlighted a significant disparity in how these benefits manifested across different racial groups. While the reduction in obesity-related cancer risk for white patients was approximately 50%, this specific reduction was not observed among black patients.

Dr. Kamat suggested that this gap might not be due to the medication’s efficacy alone. Instead, it may reflect “additional causes such as access to care, differing risk profiles and other biological differences.” This finding underscores the need for more inclusive research to understand how these drugs interact with diverse biological and socioeconomic factors.

Comparison of Risk Reduction Findings

Patient Group Observed Risk Reduction
Overall (Non-diabetic) 41%
Men Nearly 70%
White Patients ~50%
Endometrial Cancer 58%

What are the limitations of this research?

It is vital to interpret these findings with caution. The study observed patients over an average follow-up of two years, which is a relatively short window when studying cancer development. Because of this, the researchers emphasized that the data does not prove that GLP-1 drugs directly cause cancer prevention.

New study suggests a link between GLP-1s and lower cancer risk

Professor Pedro Ramirez, chair of the Department of Obstetrics and Gynecology at Houston Methodist Hospital, stated that while the findings provide “early evidence that deserves further study,” long-term clinical trials are necessary to confirm these results. Currently, cancer risk reduction should not be used as a standalone reason to prescribe these medications, but it is a critical factor for patients who are already candidates for them.

Pro Tip for Patients

If you are currently using GLP-1 medications for weight management, bring up your family history of cancer and your long-term health goals during your next physician consultation. This data provides a new, important layer for those conversations.

Frequently Asked Questions

Do GLP-1 drugs like Ozempic and Wegovy prevent cancer?

The study shows an association between GLP-1 RA use and a lower incidence of obesity-related cancers, but it does not prove that the drugs directly prevent cancer. More long-term research is required.

Do GLP-1 drugs like Ozempic and Wegovy prevent cancer?

Which GLP-1 medication showed the most promise in this study?

According to the researchers, while all formulations showed benefits, the greatest reduction in obesity-related cancers was seen among users of tirzepatide.

Who was the primary focus of this study?

The study focused on obese, non-diabetic adults in the United States, a population that is typically younger than those using these drugs to treat diabetes.

What do you think about the potential for weight-loss drugs to change cancer prevention strategies? Share your thoughts in the comments below or subscribe to our newsletter for the latest medical research updates.

June 8, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Low Adherence to Treat-to-Target Strategies in Rheumatology

by Chief Editor June 4, 2026
written by Chief Editor

For years, the gold standard for medical knowledge has been the randomized controlled trial (RCT). While these trials are essential, they often exist in a “perfect” environment that doesn’t always mirror the messy, complex reality of daily clinical practice. That is changing. As presented at the latest EULAR Congress, the integration of real-world evidence (RWE) is shifting how we manage rheumatic and musculoskeletal diseases (RMDs), moving us toward more personalized, data-driven care.

The “Treat-to-Target” Gap: Why Implementation Matters

The “Treat-to-Target” (T2T) strategy—where clinicians aim for clinical remission or low disease activity through frequent monitoring—is the cornerstone of modern rheumatology. Yet, a recent study from Italy reveals a striking reality: in practice, we are falling short.

Analysis of nearly 1,500 outpatient visits found that T2T adherence in spondyloarthritis patients was a mere 40%. The culprit? A simple, yet devastating, documentation gap. In 90% of cases where T2T wasn’t followed, it was because clinicians weren’t recording disease activity using validated indices. When the data isn’t tracked, the strategy cannot be executed.

Pro Tip: If you are living with an RMD, don’t be afraid to ask your rheumatologist, “What is my current disease activity score?” Tracking these numbers at every visit ensures you and your doctor are aligned on your treatment goals.

Weight Management and the GLP-1 Revolution

Weight management has long been a pillar of RMD care, but the emergence of GLP-1 receptor agonists (such as semaglutide and tirzepatide) has changed the conversation. Data from over 60,000 registry patients show that these medications are not just for diabetes; they are being actively used to manage weight in patients with conditions like psoriatic arthritis and ankylosing spondylitis.

Weight Management and the GLP-1 Revolution
Target Strategies

The numbers are compelling: non-diabetic users saw significant weight loss, with tirzepatide often outperforming semaglutide in head-to-head patterns. As we look to the future, the focus is shifting from “just weight loss” to understanding how these drugs impact long-term joint function and disease-specific inflammation.

Early Detection of RA-ILD: A New Frontier

Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) remains a major concern for clinicians due to its link to higher mortality rates. The ANCHOR-RA study, the largest prospective screening effort of its kind, recently uncovered that roughly 1 in 10 patients with RA and known risk factors already have undiagnosed ILD.

EULAR 2026 Congress | Live Sessions Channel 1

Key risk factors identified include:

  • Advanced age and male sex.
  • High cumulative tobacco exposure.
  • Genetic markers, specifically the MUC5B promoter variant.
  • Clinical signs such as crackles on auscultation and low oxygen saturation.
Did you know? Even if you don’t have respiratory symptoms, your rheumatologist may suggest lung function tests if you have specific risk factors. Early detection is the strongest tool we have to alter the natural history of RA-ILD.

The Smoking Paradox in Rheumatology

While smoking rates have plummeted across the general European population, the trend in the rheumatology community is more nuanced. Recent data from the Swiss Clinical Quality Management (SCQM) registry shows that while overall smoking rates among RA patients are declining, the gap between the general population and those with RA is widening—particularly among men.

This suggests that current public health messaging isn’t reaching those most at risk of developing severe rheumatic complications. It serves as a reminder that primary prevention—quitting smoking—remains the most effective “treatment” for preventing long-term cardiopulmonary damage in RMD patients.

Frequently Asked Questions (FAQ)

What is the “Treat-to-Target” strategy?

We see a clinical approach where doctors and patients set a specific goal (usually remission or low disease activity) and adjust medications frequently until that goal is met.

Why is RA-ILD so dangerous?

Interstitial lung disease involves scarring of the lung tissue, which can reduce oxygen intake and is associated with a higher risk of mortality in patients with rheumatoid arthritis.

Can GLP-1 drugs help with joint pain?

While these drugs are primarily for weight loss and diabetes, researchers are currently investigating if the resulting weight reduction and potential anti-inflammatory effects improve overall joint health and function in RMD patients.


Are you interested in learning more about how real-world data is changing your treatment options? Subscribe to our newsletter for the latest updates in rheumatology research, or join the conversation in the comments section below.

June 4, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Can GLP-1 Drugs Help Prevent Breast Cancer? New Study Findings

by Chief Editor June 4, 2026
written by Chief Editor

A New Frontier in Cancer Prevention: Could Weight-Loss Drugs Change the Game?

For decades, the medical community has searched for pharmacological ways to lower breast cancer risk beyond traditional hormone-blocking therapies. Now, a compelling new study published in JCO Oncology Practice suggests that the next breakthrough in cancer prevention might already be sitting in our medicine cabinets.

Researchers investigating the link between glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—widely known for treating type 2 diabetes and obesity—and breast cancer incidence have uncovered data that could fundamentally shift how we approach oncology prevention. With over 100,000 women tracked in a major health system study, the findings indicate a significant, measurable reduction in breast cancer diagnosis among those using these medications.

Did you know? The study found that women using GLP-1 agonists had a 30% lower odds of being diagnosed with breast cancer compared to those who did not use the drugs, even after adjusting for factors like age, race, and breast density.

The Science Behind the Metabolic Link

Why would a weight-loss drug influence cancer risk? The answer likely lies in the complex relationship between metabolic health and cellular biology. Obesity is a well-established, modifiable risk factor for breast cancer, largely due to the systemic inflammation and hormonal shifts associated with excess adipose tissue.

View this post on Instagram about Pro Tip
From Instagram — related to Pro Tip

GLP-1 agonists do more than just suppress appetite. They are known to enhance metabolic regulation and reduce systemic inflammation—a hallmark of cancer development. Emerging laboratory models suggest these drugs may also alter cellular energy metabolism, potentially slowing the proliferation and viability of breast cancer cells.

Beyond Weight Loss: The GIP and GLP-1 Synergy

Recent research into dual-action drugs, such as those targeting both GIP and GLP-1 receptors, has shown promise in mouse models for reducing tumor growth. While these findings are experimental, they provide a biological roadmap for how future preventative treatments might work by targeting multiple hormonal pathways simultaneously.

Pro Tip: Always consult with your primary care physician or an oncologist before considering any medication changes. While these findings are exciting, they are currently observational and should not replace standard screening protocols like mammograms.

Bridging the Gap: From Observational Data to Clinical Trials

While the statistics are encouraging, experts urge caution. This study was observational, meaning it identifies an association rather than a direct cause-and-effect relationship. Because GLP-1 users often visit doctors more frequently, there is always the question of whether increased screening leads to higher detection or if the medication provides a genuine protective shield.

To move these findings into clinical practice, the medical community needs large-scale, prospective clinical trials. These studies will be essential to determine:

  • Optimal Duration: How long must a patient be on the medication to see preventative benefits?
  • Dosage Requirements: Is there a “sweet spot” for cancer risk reduction that differs from standard weight-loss dosing?
  • Patient Selection: Which specific populations—based on genetic risk or metabolic profile—would benefit most?

A Potential Alternative for High-Risk Patients

Current preventative options, such as tamoxifen, are highly effective but can come with hard side effects that lead many women to discontinue treatment. If future research confirms that GLP-1 agonists provide a similar risk-reduction profile with a different side-effect profile, it could offer a vital alternative for women who cannot tolerate traditional chemoprevention.

Meet Dr. Jeffrey Peppercorn, JCO Oncology Practice Editor-In-Chief

By expanding the toolkit for breast cancer prevention, we move closer to a personalized medicine approach where metabolic health is viewed as a primary pillar of cancer survivorship, and prevention.

Frequently Asked Questions

1. Does this mean I should start taking GLP-1 drugs to prevent breast cancer?

No. These findings are preliminary and observational. GLP-1 agonists are prescription medications with specific side effects and should only be used under the guidance of a healthcare provider for approved indications like diabetes or weight management.

2. How much did the breast cancer risk actually drop?

In the study’s matched analysis, the breast cancer risk was 1.62% among GLP-1 users compared to 2.31% in the non-user group, representing an absolute risk reduction of 0.69% during the study period.

3. Is weight loss the only reason for the reduced risk?

While weight loss is a significant factor in reducing cancer risk, researchers believe the metabolic and anti-inflammatory properties of GLP-1 medications may provide additional protective benefits that go beyond simple calorie reduction.


What are your thoughts on the intersection of metabolic health and oncology? Join the conversation in the comments below, or subscribe to our newsletter for the latest updates on cancer research breakthroughs.

June 4, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Weight Loss Surgery Linked to Lower Cancer Mortality in Women

by Chief Editor May 25, 2026
written by Chief Editor

The Future of Obesity Treatment: Why Precision Medicine is the New Frontier

For decades, the medical community viewed weight loss primarily through the lens of caloric balance. However, groundbreaking long-term research—most notably the Swedish Obese Subjects (SOS) study—is fundamentally shifting that narrative. We are entering an era where weight management is no longer just about the scale; it is about metabolic health, genetic profiling, and targeted cancer prevention.

As we see a surge in the use of high-efficacy weight-loss medications, understanding the biological “why” behind cancer risk reduction has never been more critical. The future of obesity care lies in personalized medicine, where treatment plans are as unique as the patient’s DNA.

Decoding the Link: Insulin, Genetics, and Cancer

Recent studies have highlighted that weight loss does not impact every individual’s cancer risk equally. Researchers have identified that women, in particular, see a significant reduction in cancer-related mortality following bariatric surgery. The missing piece of the puzzle appears to be insulin levels.

Webinar: Study at the University of Gothenburg

High circulating insulin, often a byproduct of metabolic syndrome, acts as a growth factor for certain cells. When this is coupled with specific genetic markers, such as the FTO gene variant, the risk profile changes dramatically. Patients carrying this variant who underwent surgical intervention saw their breast cancer risk plummet by up to 64% when they also managed their insulin levels effectively.

Pro Tip: Don’t wait for a diagnosis to assess your metabolic health. Regular screening for fasting insulin and HbA1c levels can provide a clearer picture of your long-term health risks than BMI alone.

The Shift Toward Precision Prevention

The “one-size-fits-all” approach to obesity is becoming obsolete. As we look ahead, clinical strategies will likely involve a multi-pronged diagnostic process:

  • Genetic Screening: Identifying markers like the FTO variant to predict how a patient will respond to specific metabolic interventions.
  • Metabolic Profiling: Using insulin and inflammatory markers to determine the urgency of intervention.
  • Tailored Pharmacotherapy: Matching the patient with GLP-1 agonists or other emerging treatments based on their specific metabolic signatures.

Did You Know?

The Swedish Obese Subjects (SOS) study is one of the longest-running investigations in medical history, with some participants followed for over 30 years. This longitudinal data provides the “gold standard” for understanding the link between obesity and long-term cancer outcomes.

Did You Know?
Weight Loss Surgery Linked

Frequently Asked Questions (FAQ)

Does weight loss surgery guarantee cancer prevention?
No medical procedure provides a guarantee. However, research shows a significant correlation between sustained weight loss and reduced cancer incidence, particularly in women with high insulin levels.
Can genetic testing tell me if I am at risk?
While genetic markers like the FTO variant are linked to higher risks, they are only one piece of the puzzle. Lifestyle, metabolic health, and environmental factors play equally important roles.
Are new weight-loss drugs as effective as surgery for cancer prevention?
While current research primarily focuses on bariatric surgery, the medical community is actively investigating whether the metabolic benefits of new GLP-1 medications produce similar long-term cancer-preventive effects.

What In other words for You

If you are navigating your own health journey, the takeaway is clear: metabolic health is foundational. Whether through surgical intervention or the latest medical therapies, the goal is to stabilize your body’s internal chemistry. Talk to your primary care physician about a comprehensive metabolic panel—it is the first step toward taking control of your long-term health.


Are you interested in how the latest metabolic research could change your health outcomes? Subscribe to our weekly newsletter for the latest updates on precision medicine and weight-loss science. Join the conversation in the comments below: How has your understanding of weight loss changed in the last five years?

May 25, 2026 0 comments
0 FacebookTwitterPinterestEmail
Tech

How Weight-Loss Drugs Reshape Brain Cells: NIH Study Findings

by Chief Editor May 22, 2026
written by Chief Editor

Unlocking the Cellular Secrets of GLP-1 Weight Loss

The rise of GLP-1 receptor agonists has transformed the landscape of weight management. While the clinical benefits of these medications are well-documented, the precise biological “nuts and bolts” occurring within our neurons have remained largely a mystery. A recent study conducted by researchers at the National Institutes of Health (NIH) is finally pulling back the curtain on these intracellular processes.

Unlocking the Cellular Secrets of GLP-1 Weight Loss
Loss Drugs Reshape Brain Cells Researchers

By studying brain tissue in mice, researchers identified specific signaling molecules that dictate how the brain responds to drugs like semaglutide. This discovery could be the key to moving beyond current treatment plateaus and developing more effective, longer-lasting therapies.

Did you know? Researchers observed that cAMP responses—a critical signaling pathway—varied across cells on a continuum rather than functioning as a simple “on or off” switch.

Why Do Treatment Effects Plateau?

One of the most persistent challenges for patients using GLP-1 medications is the eventual plateau in weight loss. According to Andrew Lutas, Ph.D., an investigator at NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the scientific community has historically understood the brain regions involved, but not the specific cellular mechanisms at play.

The NIH research team discovered that some neurons sustain elevated signaling levels in the presence of semaglutide, while others show only temporary spikes. This inconsistency may occur because some neurons internalize or degrade their GLP-1 receptors over time. By understanding these limitations, scientists are beginning to map out why individual responses to medication vary so significantly between patients.

The Future of Sustained Treatment

The study highlights a potential path toward enhancing treatment efficacy. Researchers successfully used roflumilast, a drug that inhibits the enzyme PDE4, to prevent the degradation of cAMP. This intervention helped “skew” neurons toward a more sustained response.

$STVN: are oral GLP-1s really a death blow? | Aurelian Research's Leo Trudel

Potential Clinical Breakthroughs

  • Extended Dosing Intervals: By stabilizing cellular responses, future therapies might not require as frequent administration.
  • Overcoming Plateaus: Targeted modulation of cAMP could help patients bypass the weight-loss ceilings currently observed in clinical practice.
  • Personalized Medicine: Understanding the continuum of cellular responses may eventually allow clinicians to tailor dosages based on a patient’s unique neuronal signaling profile.
Pro Tip: While these findings are promising, experts emphasize that this is a developing area of science. Future research aims to transition from observing signaling over a few hours to tracking these effects over days and weeks.

Frequently Asked Questions (FAQ)

What are GLP-1 receptor agonists?
They are a class of medications, such as semaglutide, that are widely used to support weight loss by targeting specific pathways in the brain.
Why do weight-loss effects sometimes plateau?
Research suggests that neurons may internalize or degrade GLP-1 receptors over time, leading to a diminished response to the medication.
Can we make these drugs work longer?
The NIH study suggests that modulating intracellular signaling molecules, such as inhibiting the enzyme PDE4, could potentially sustain the effects of the medication.

What are your thoughts on the future of metabolic medicine? Have you found these insights helpful? Join the conversation below and let us know your questions, or subscribe to our health newsletter for the latest updates on medical research.

May 22, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Gary Neville’s Fitness Routine: How Exercise Transformed His Life After Football

    June 18, 2026
  • The Century-Long Intersection of Football, Politics, and Propaganda

    June 18, 2026
  • Why Heart Patients With Implants Should Avoid AirPods: Keep Magnetic Devices 15cm Away

    June 18, 2026
  • Major Funding Boost for Healthcare Systems

    June 18, 2026
  • The Giant Underground Organism Protecting Earth

    June 18, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World